Price · as of 2025-12-31
$293.86
Market cap 33.87B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $288.17 | -1.94% |
| Intrinsic Value(DCF) | $3,863.14 | +1,214.62% |
| Graham-Dodd Method(GD) | $53.14 | -81.92% |
| Graham Formula(GF) | $122.56 | -58.29% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $27.88 | $37.90 | $0.00 | $0.00 | $41.42 |
| 2016 | $39.99 | $31.61 | $6.91 | $0.00 | $291.26 |
| 2017 | $151.97 | $3,460.73 | $27,065.81 | $5.23 | $0.00 |
| 2018 | $128.75 | $1,055.93 | $16.46 | $0.00 | $96.48 |
| 2019 | $153.31 | $61.32 | $14,169.82 | $0.00 | $0.00 |
| 2020 | $321.70 | $128.68 | $22.80 | $0.00 | $359.38 |
| 2021 | $161.53 | $104.65 | $44,008.86 | $0.00 | $0.00 |
| 2022 | $216.24 | $89.92 | $837.41 | $0.00 | $0.00 |
| 2023 | $158.52 | $80.96 | $46,782.18 | $0.00 | $0.00 |
| 2024 | $247.07 | $135.87 | $13,344.08 | $1.03 | $0.00 |
| 2025 | $314.36 | $288.17 | $13,569.04 | $53.14 | $122.56 |
AI valuation
Our deep-learning model estimates BeOne Medicines Ltd.'s (ONC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $288.17
- Current price
- $293.86
- AI upside
- -1.94%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3,863.14
+1,214.62% upside
Graham-Dodd
$53.14
-81.92% upside
Graham Formula
$122.56
-58.29% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ONC | BeOne Medicines Ltd. | $293.86 | 33.87B | -2% | +1,215% | -82% | -58% | 119.49 | 7.86 | 6.42 | 49.99 | — | 7.98 | 87.49% | 8.37% | 5.37% | 7.46% | 22.87% | 4.07% | 0.25 | 7.68 | 3.41 | 2.96 | -5.60 | -63742.00% | 4023.00% | -24061.00% | 2.75% | 0.62 | 69.99% | 0.00% | 0.00% | 5.56% | 68.95 | 32.74 | 5.77 | 5.43 |
| A | Agilent Technologies, Inc… | $121.38 | 34.41B | -21% | -48% | -87% | -44% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ALC | Alcon Inc. | $87.18 | 42.49B | -32% | -61% | -65% | -71% | 42.77 | 1.90 | 4.03 | 19.38 | — | 11.11 | 55.24% | 13.08% | 9.42% | 4.50% | 4.55% | 3.17% | 0.24 | — | 2.12 | 1.16 | 1.58 | -341.00% | 494.00% | 2281.00% | 4.12% | 0.74 | 6.84% | 0.40% | 16.90% | 2.12% | 33.49 | 26.36 | 4.38 | 3.24 |
| GEHC | GE HealthCare Technologie… | $84.27 | 38.41B | +5% | -50% | -83% | -31% | 16.99 | 3.53 | 1.77 | 11.12 | 351.11 | -8.63 | 39.99% | 13.39% | 10.10% | 22.88% | 13.96% | 6.15% | 0.96 | 6.14 | 1.18 | 0.93 | 1.45 | 484.00% | 484.00% | -284.00% | 4.12% | 0.22 | 9.78% | 0.17% | 3.00% | 3.44% | 15.24 | 27.95 | 2.04 | 1.89 |
| HUM | Humana Inc. | $190.54 | 22.92B | -18% | +504% | -67% | -8% | 18.99 | 1.28 | 0.17 | 5.17 | — | 2.83 | 14.54% | 1.12% | 0.92% | 6.98% | 6.79% | 2.49% | 0.70 | 2.30 | 2.00 | 1.42 | 2.81 | -140.00% | 1006.00% | -8432.00% | 1.66% | 0.06 | 2.12% | 1.91% | 36.20% | 5.92% | 10.34 | 40.07 | 0.12 | 4.42 |
| INSM | Insmed Incorporated | $149.33 | 31.85B | -50% | +3,425% | — | — | -24.48 | 42.30 | 51.55 | -26.12 | -162.35 | 61.87 | 79.41% | -194.04% | -210.54% | -249.28% | -969.45% | -59.53% | 1.04 | -14.04 | 3.83 | 3.35 | -0.22 | 1508.00% | 6673.00% | 3709.00% | -3.10% | -1.99 | -797.14% | 0.00% | 0.00% | 1.60% | -26.00 | -31.62 | 50.46 | 8.06 |
| IQV | IQVIA Holdings Inc. | $178.81 | 30.45B | -2% | -53% | — | -39% | 22.01 | 4.61 | 1.84 | 12.70 | 471.04 | -1.99 | 26.28% | 14.02% | 8.34% | 21.65% | 9.92% | 4.79% | 2.49 | 3.14 | 0.75 | 0.67 | 4.10 | 467.00% | 587.00% | -298.00% | 6.85% | 0.32 | 10.54% | 0.00% | 0.00% | 4.15% | 19.23 | 21.45 | 2.70 | 1.83 |
| MTD | Mettler-Toledo Internatio… | $1,366.69 | 27.92B | -28% | -53% | -87% | -63% | 31.42 | -1155.46 | 6.78 | 23.96 | 851.91 | -26.22 | 57.52% | 27.78% | 21.59% | -1154.87% | 44.16% | 25.00% | -99.14 | 16.32 | 1.14 | 0.71 | 1.84 | 369.00% | 398.00% | -183.00% | 3.11% | 0.80 | 40.43% | 0.00% | 0.00% | 2.93% | 26.45 | 34.86 | 7.35 | 10.00 |
| NTRA | Natera, Inc. | $208.04 | 29.01B | -52% | +773% | -99% | — | -92.12 | 14.68 | 10.34 | -113.19 | — | 14.68 | 60.30% | -13.10% | -11.22% | -19.42% | -59.87% | -12.28% | 0.16 | -20.80 | 4.00 | 3.73 | 5.12 | -5952.00% | 5675.00% | -12420.00% | 0.39% | 0.39 | 18.65% | 0.00% | 0.00% | 3.18% | -75.40 | 242.08 | 9.88 | 21.78 |
| PHG | Koninklijke Philips N.V. | $32.00 | 30.68B | +25% | -54% | -95% | -76% | 28.63 | 2.34 | 1.44 | 11.71 | — | -29.02 | 45.18% | 7.98% | 5.02% | 7.80% | 6.50% | 3.20% | 0.74 | 4.28 | 1.32 | 0.84 | 2.00 | -22400.00% | -104.00% | -3406.00% | 3.49% | 0.15 | 5.36% | 1.28% | 36.60% | 1.28% | 21.71 | 34.62 | 1.73 | 2.09 |
| RMD | ResMed Inc. | $256.26 | 37.41B | -10% | -40% | -86% | -35% | 28.88 | 6.78 | 7.86 | 20.96 | 77.17 | 16.47 | 59.36% | 32.75% | 27.22% | 25.86% | 25.33% | 18.62% | 0.14 | 133.66 | 3.44 | 2.16 | -0.19 | 3743.00% | 984.00% | 2918.00% | 4.11% | 1.72 | 29.91% | 0.77% | 22.20% | 3.96% | 23.79 | 24.13 | 7.79 | 13.72 |
About BeOne Medicines Ltd.
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
- CEO
- John V. Oyler
- Employees
- 11K
- Beta
- 0.52
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3,863.14 ÷ $293.86) − 1 = +1,214.62% (DCF, example).